Naslov
HCV Antigen in anti-HCV positive sera of patients with HCV infection

Autori
Burek, Vitomir

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstract Book / 9th International Meeting on HCV and Related Viruses / Abrignani, S. ; Houghton, M. ; Rice, C. - San Diego (CA) : Biblo-press, 2002, 168-168

Skup
9th International Meeting on HCV and Related Viruses

Mjesto i datum
San Diego (CA), Sjedinjene Američke Države, 07.07.2002. - 11.07.2002

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
HCV infection; HCV antigen

Sažetak
Only ways to detect HCV viremia have beendetection of HCV RNA by nucleid acid amplifying test (NAT). Nats wew sensitive butentails substantial operational complexity and are very expensive for screening. Recently it was developed a sensitive EIA for HCVAg detection during a period when it is free, not bound with antibody, because they were not yet developed (during pre-seroconversion period, "window" period). Following a dynamics of appearing and disappearing of HCVAg in some of our patients with acute HCV infection we found simultaneous presence of HCVAg and anti-HCV mainly in the period when HCVAg were near diappearance. That was a reason that we used this test trying to detect HCVAg in the presence of antibody to HCV (anti-HCV)on a large scale.A method of enzyme immunoassay (EIA) for detecting HCV core antigen (HCV cAg)in serum (ORTHO Antibody to HCV Core Antigen ELISA Test System) was used. We tested 250 sera of 50 patients with HCV infection. All of them were anti-HCV positive and we followed them through period of 3-12 months having in average 5 sera for each patient. All of them were positive for anti-HCV through the whole period of testing. Among them we found a certain number of patients with HCVAg positivity in three different patterns: I. group with HCVAg appearing in the beginning and diappearing some time after, II. group with negative HCVAg at the begining and appearing some time after, and III. group with positive HCVAg simultaneously with anti-HCV from the very beginning. It can be concluded that ELISA intended for detection of HCVAg could detect its presence simultaneously with anti-HCV in some special situations. Namely if sample contains high titers of anti-core antibody competing monoclonal antibodies for binding to core antigen, interference will occur in screening assay. If the epitopes of human antibody to core antigens differ from those of monoclonal antibodies, no interference will be observed.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA